Sunday, September 4, 2011

 etomidate speech and memory test (eSAM)

Another less known use for etomidate is to determine speech lateralization in patients prior to performing lobectomies to remove epileptogenic centres in the brain. 

Etomidate is injected into the carotid artery and will anesthetize the ipisilateral brain hemisphere for 5–10 minutes. During such time, rudimentary speech and memory tasks are performed in order to determine if removal of a particular part of a hemisphere will affect the patients language abilities or induce severe memory impairments. 

Prior to the procedure the patient is shown a series of objects and during the procedure shown another series of objects. Once the injection has worn off, the patient is shown some of the same objects and asked whether or not they saw them that day. If the patient doesn't recognize the objects that were shown during the procedure, it is clear that the medial temporal structures that were left un-anesthetized during the procedure are not functioning properly.



Etomidate speech and memory test (eSAM) A new drug and improved intracarotid procedure - Neurology December 13, 2005 vol. 65 no. 11 1723-1729

Saturday, September 3, 2011

A note on Acomprosate

Acomproste (Campra), is a drug used for treating alcohol dependence but effective only during abstinence from alcohol.

Withdrawal from alcohol induces a surge in release of excitatory neurotransmitters like glutamate, which activates N-methyl-D-aspartate receptors (NMDARs). Acamprosate reduces this glutamate surge.

Side effects include diarrhea, irregular heart beat, hypotension, headaches, insomnia, and impotence. It is relatively contraindicated in renal failure.

Recommended dose is 666 mg (taken as two 333-mg tablets) three times daily.

Acamprosate is also said to be an effective treatment for tinnitus.

Friday, September 2, 2011

 Interesting case report on Hypokalemia induced Nephrogenic DI 


Reference: Buridi A, Corman L, Redinger R., Hypokalemic nephropathy and nephrogenic diabetes insipidus due to excessive consumption of a soft drink. - South Med J. 1998 Nov; 91(11):1079-82.


"Chronic diarrhea commonly causes hypokalemia. However, life-threatening hypokalemia due to chronic diarrhea has not been reported in the adult caused by chronic ingestion of a fructose beverage. We report an adult patient who had severe hypokalemia from chronic osmotic diarrhea as a result of drinking 4 to 6 liters of Big Red daily for several months. This resulted in sustained hypokalemia, complicated by hypokalemic nephropathy and subsequent nephrogenic diabetes insipidus. All abnormalities cleared with potassium replacement, salt restriction, modest thiazide treatment, and abstinence from Big Red."

Thursday, September 1, 2011

Procalcitonin Algorithms for Antibiotic Therapy Decisions

Reference: Procalcitonin Algorithms for Antibiotic Therapy Decisions - A Systematic Review of Randomized Controlled Trials and Recommendations for Clinical Algorithms - Arch Intern Med. 2011;171(15):1322-1331.

Previous randomized controlled trials suggest that using clinical algorithms based on procalcitonin levels, a marker of bacterial infections, results in reduced antibiotic use without a deleterious effect on clinical outcomes. However, algorithms differed among trials and were embedded primarily within the European health care setting. Herein, we summarize the design, efficacy, and safety of previous randomized controlled trials and propose adapted algorithms for US settings.

We performed a systematic search and included all 14 randomized controlled trials (N = 4467 patients) that investigated procalcitonin algorithms for antibiotic treatment decisions in adult patients with respiratory tract infections and sepsis from primary care, emergency department (ED), and intensive care unit settings. We found no significant difference in mortality between procalcitonin-treated and control patients overall (odds ratio, 0.91; 95% confidence interval, 0.73-1.14) or in primary care (0.13; 0-6.64), ED (0.95; 0.67-1.36), and intensive care unit (0.89; 0.66-1.20) settings individually. A consistent reduction was observed in antibiotic prescription and/or duration of therapy, mainly owing to lower prescribing rates in low-acuity primary care and ED patients, and shorter duration of therapy in moderate- and high-acuity ED and intensive care unit patients. Measurement of procalcitonin levels for antibiotic decisions in patients with respiratory tract infections and sepsis appears to reduce antibiotic exposure without worsening the mortality rate. We propose specific procalcitonin algorithms for low-, moderate-, and high-acuity patients as a basis for future trials aiming at reducing antibiotic overconsumption.